Report Overview

The Canadian Prostate Cancer drugs market size stood at around USD 110 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Prostate cancer is the most common type of cancer in Canadian men, followed by colorectal, lung, and bladder cancers. It is 3^rd leading cause of death from cancer in men in Canada. Recent analyses from the Canadian Cancer Society suggest that 1 in 7 men will be diagnosed with prostate cancer in their lifetime and that 1 in 29 will die from the disease. Prostate cancer develops when abnormal cells in the prostate gland are forming a malignant tumor in an uncontrolled way. In 2020, an estimated 23,300 new cases of prostate cancer were diagnosed in Canada.Early (localized) prostate cancer refers to cancer cells that have grown but do not appear to have spread beyond the prostate.



Market Drivers

The rise in prevalence of Prostate Cancer, growing awareness about various types of Cancers, Advancements in the Healthcare Field are major market drivers for the Prostate cancer drugs market in Canada, it is the most common cancer diagnosed in men in Canada and the 3^rd most common cause of cancer death in men. On average, 64 Canadian men will be diagnosed with prostate cancer, and 11 Canadian men will die from prostate cancer every day. The prostate cancer market has a high demand for novel drugs that concentrate on unmet needs, such as improved survival time, less toxicity, better progression-free survival, improved effectiveness, and lesser cost. Altering lifestyle, technological advancements in researching for new techniques to fight prostate cancer, increase in the funding in both the public and private sectors in the field of drug advancement are some of the key reasons driving the growth of the Canadian prostate cancer market.